Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as azacitidine and arsenic trioxide, work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer
cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of azacitidine when
given together with arsenic trioxide and to see how well they work in treating patients with
myelodysplastic syndromes.
Phase:
Phase 1
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
Celgene Corporation CTI BioPharma National Cancer Institute (NCI)